参考文献：Jing Zhou, Fa-Da Wang, Lan-Qing Li, Yu-Jin Li, Shi-Yan Wang, En-Qiang Chen. Antiviral Therapy Favors a Lower Risk of Liver Cirrhosis in HBeAg-negative Chronic Hepatitis B with Normal Alanine Transaminase and HBV DNA Positivity. J Clin Transl Hepatol 2023. doi: 10.14218/JCTH....
参考文献: van Bömmel F, Stein K, Heyne R, et al. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B. J Hepatol. 2023;78(5):926-936.
导读 在《慢性乙型肝炎防治指南(2022年版)》中,抗病毒治疗的指征被进一步扩大,然而,对于ALT水平正常、HBeAg阴性、HBV DNA阳性的慢性乙型肝炎(chronic hepatitis B,CHB)患者,抗病毒治疗的益处仍缺乏直接的临床数据。 近日,四川大学华西医院...
在HBeAg阴性不确定期患者中,基于HBcrAg的GZ-HCC评分比其他基于HBV DNA的风险评分更好地预测HCC,这可能有助于优化其临床管理。 参考文献:Tseng TC, Hosaka T, Liu CJ, et al. HBcrAg-based risk score performs better than HBV DNA-ba...
参考文献:Jing Zhou, Fa-Da Wang, Lan-Qing Li, Yu-Jin Li, Shi-Yan Wang, En-Qiang Chen. Antiviral Therapy Favors a Lower Risk of Liver Cirrhosis in HBeAg-negative Chronic Hepatitis B with Normal Alanine Transaminase and HBV DNA Positivity. J Clin Transl Hepatol 2023. doi: 10.14218/JCTH.202...
在HBeAg阴性不确定期患者中，基于HBcrAg的GZ-HCC评分比其他基于HBV DNA的风险评分更好地预测HCC，这可能有助于优化其临床管理。参考文献：Tseng TC, Hosaka T, Liu CJ, et al. HBcrAg-based risk score performs better than HBV DNA-based score for HCC prediction in HBeAg-negative grey zone patients. JHEP...
One-year safety results of the Nuc-Stop Study, an open-label study on stopping antiviral therapy in HBeAg negative chronic hepatitis B. EASL2021. Abstracts (PO-111). 往期内容请点击 【肝霖特写 | 084】深度解析:HBeAg阴性慢乙肝患者NA停药后复发风险高,需慎重!mp.weixin.qq.com/s?__biz=Mzg...
风险评分模型可用于预测未经治慢性乙型肝炎(chronic hepatitis B,CHB)患者的肝细胞癌(hepatocellular carcinoma,HCC)风险。然而,其在HBeAg阴性不确定期患者中的预测准确性尚不明确。近日,中国台湾学者构建了一种基于HBcrAg水平的CHB患者HCC风险评分模型(GZ-HCC评分模型)。研究显示:在HBeAg阴性不确定期患者中,基于HBcrAg的...
因此NA治疗的慢乙肝患者获得HBsAg清除可能是最安全的停药策略。 参考文献: Hall SAL, Vogrin S, Wawryk O, et al. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis[J]. Gut, 2021.
Wang J, Zhu L, Zhang S, et al. Clinical outcomes of treatment-naïve HBeAg negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA[J]. Emerg Microbes Infect. 2024, 13(1): 2339944.